Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRNX Crinetics Pharmaceuticals	$30.94 +3.4%	$31.47	$24.10 ▼ $62.53	$2.80B	0.28	834,748 shs	574,500 shs
PCRX Pacira BioSciences	$24.62 -0.5%	$25.46	$11.16 ▼ $29.33	$1.15B	0.52	959,551 shs	435,197 shs
RCUS Arcus Biosciences	$8.77 +1.6%	$8.77	$6.50 ▼ $18.98	$913.79M	0.83	867,134 shs	681,000 shs
TGTX TG Therapeutics	$37.30 +2.0%	$37.11	$16.65 ▼ $46.48	$5.80B	1.94	2.93 million shs	1.67 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRNX Crinetics Pharmaceuticals	+3.44%	+0.29%	+3.97%	-10.34%	-32.24%
PCRX Pacira BioSciences	-0.49%	+0.94%	-4.39%	+0.82%	-15.25%
RCUS Arcus Biosciences	+1.39%	+0.40%	-3.10%	+6.31%	-46.52%
TGTX TG Therapeutics	+2.02%	+6.57%	+7.90%	-8.56%	+102.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRNX Crinetics Pharmaceuticals	3.6411 of 5 stars	3.5	0.0	3.7	3.3	2.5	0.0
PCRX Pacira BioSciences	2.2941 of 5 stars	1.2	1.0	3.9	2.0	2.5	0.6
RCUS Arcus Biosciences	2.3418 of 5 stars	4.4	0.0	0.0	2.5	1.7	0.0
TGTX TG Therapeutics	3.0597 of 5 stars	1.4	1.0	3.5	2.2	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRNX Crinetics Pharmaceuticals	2.91	Moderate Buy	$74.56	140.97% Upside
PCRX Pacira BioSciences	2.33	Hold	$26.44	7.41% Upside
RCUS Arcus Biosciences	2.89	Moderate Buy	$21.29	142.85% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$40.80	9.38% Upside

Current Analyst Ratings Breakdown

Latest TGTX, RCUS, PCRX, and CRNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	PCRX Pacira BioSciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $30.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
4/23/2025	RCUS Arcus Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $14.00
4/8/2025	PCRX Pacira BioSciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/8/2025	PCRX Pacira BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$48.00 ➝ $65.00
3/25/2025	CRNX Crinetics Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRNX Crinetics Pharmaceuticals	$1.04M	2,785.49	N/A	N/A	$14.29 per share	2.17
PCRX Pacira BioSciences	$700.97M	1.63	$4.30 per share	5.73	$16.86 per share	1.46
RCUS Arcus Biosciences	$258M	3.60	N/A	N/A	$5.30 per share	1.65
TGTX TG Therapeutics	$329M	18.00	$0.12 per share	304.76	$1.43 per share	26.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRNX Crinetics Pharmaceuticals	-$298.41M	-$3.82	N/A	N/A	N/A	N/A	-30.95%	-28.12%	8/6/2025 (Estimated)
PCRX Pacira BioSciences	-$99.56M	-$2.28	N/A	9.58	N/A	-14.78%	13.78%	7.00%	7/29/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$4.19	N/A	N/A	N/A	-258.94%	-70.58%	-32.97%	8/4/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.24	155.42	37.30	N/A	10.13%	18.88%	7.05%	8/5/2025 (Estimated)

Latest TGTX, RCUS, PCRX, and CRNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CRNX Crinetics Pharmaceuticals	-$0.99	-$1.04	-$0.05	-$1.04	$0.10 million	$0.36 million
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRNX Crinetics Pharmaceuticals	N/A	22.53	22.53
PCRX Pacira BioSciences	0.48	2.41	1.99
RCUS Arcus Biosciences	0.09	5.37	5.37
TGTX TG Therapeutics	1.03	4.02	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRNX Crinetics Pharmaceuticals	98.51%
PCRX Pacira BioSciences	99.73%
RCUS Arcus Biosciences	92.89%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
CRNX Crinetics Pharmaceuticals	6.00%
PCRX Pacira BioSciences	6.40%
RCUS Arcus Biosciences	9.60%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRNX Crinetics Pharmaceuticals	210	93.63 million	88.01 million	Optionable
PCRX Pacira BioSciences	720	46.29 million	43.33 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	95.72 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable

TGTX, RCUS, PCRX, and CRNX Headlines

Recent News About These Companies

Assenagon Asset Management S.A. Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 20, 2025 | marketbeat.com

Insider Selling: Yann Echelard Unloads $369K Of TG Therapeutics Stock

June 17, 2025 | benzinga.com

Are Options Traders Betting on a Big Move in TG Therapeutics Stock?

June 17, 2025 | msn.com

Yann Echelard Sells 10,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) Stock

June 17, 2025 | insidertrades.com

Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sells 10,000 Shares of Stock

June 16, 2025 | marketbeat.com

Cantor Fitzgerald Estimates TG Therapeutics FY2026 Earnings

June 10, 2025 | marketbeat.com

GAMMA Investing LLC Purchases 176,573 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

June 9, 2025 | marketbeat.com

TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Month

June 7, 2025 | uk.finance.yahoo.com

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 6, 2025 | globenewswire.com

Wellington Management Group LLP Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 6, 2025 | marketbeat.com

Two Sigma Advisers LP Sells 214,800 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

June 6, 2025 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Trading Up 6.2% - Still a Buy?

June 5, 2025 | marketbeat.com

Mackenzie Financial Corp Cuts Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 5, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 1, 2025 | marketbeat.com

NorthCrest Asset Manangement LLC Invests $448,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 31, 2025 | marketbeat.com

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 30, 2025 | theglobeandmail.com

Man Group plc Purchases Shares of 9,589 TG Therapeutics, Inc. (NASDAQ:TGTX)

May 29, 2025 | marketbeat.com

TG Therapeutics: Estimates Could Soon Be Raised Again

May 28, 2025 | seekingalpha.com

Bank of America Corp DE Has $6.95 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 28, 2025 | marketbeat.com

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 27, 2025 | globenewswire.com

Connecticut Wealth Management LLC Sells 13,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

May 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX, RCUS, PCRX, and CRNX Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

$30.94 +1.03 (+3.44%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$31.37 +0.43 (+1.39%)

As of 04:05 AM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Pacira BioSciences NASDAQ:PCRX

$24.62 -0.12 (-0.49%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$24.52 -0.11 (-0.43%)

As of 06/24/2025 05:51 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Arcus Biosciences NYSE:RCUS

$8.76 +0.14 (+1.56%)

Closing price 06/24/2025 03:59 PM Eastern

Extended Trading

$8.49 -0.28 (-3.14%)

As of 06/24/2025 07:59 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

TG Therapeutics NASDAQ:TGTX

$37.30 +0.74 (+2.02%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$37.52 +0.22 (+0.58%)

As of 04:18 AM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time